Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review (Netherlands) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, May 23, 2016

Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review (Netherlands)



abstract

Review
19 May 2016

Highlights

Over 10% of all women with epithelial ovarian cancer (EOC) have a germline BRCA mutation.
Applying referral criteria leads to missing BRCA mutation carriers.
We strongly recommend to refer all women with EOC for genetic testing.

The presence of a germline BRCA1/2 mutation improves options for tailored risk-reducing strategies and treatment in both breast and ovarian cancer patients and their relatives. Currently, referral for germline BRCA1/2 mutation testing of women with epithelial ovarian cancer (EOC) varies widely, based on different criteria, such as age of onset, family history of breast and/or ovarian cancer and histological type of EOC. The overall probability of a germline BRCA1/2 mutation in women with EOC is above 10%, and a substantial part of the germline BRCA1/2 mutation carriers is missed when applying these criteria for referral. Therefore, we strongly recommend referral of all women with EOC for genetic counselling and DNA analysis.

 

0 comments :

Post a Comment

Your comments?